USANA Health Sciences reported net sales of $250 million for Q1 2025, a 10% increase year-over-year, with diluted EPS of $0.49 and adjusted diluted EPS of $0.73. Net earnings were $9.4 million. The company reiterated its full-year 2025 outlook.
Net sales increased by 10% year-over-year to $250 million, and 12% in constant currency.
Net earnings were $9.4 million, a decrease from $16.5 million in the prior year.
Diluted EPS was $0.49, while adjusted diluted EPS was $0.73.
The company reiterated its fiscal year 2025 outlook, anticipating consolidated top line growth of 8% to 17%.
USANA Health Sciences reiterated its fiscal year 2025 outlook, anticipating consolidated net sales between $920 million and $1.0 billion, and adjusted EBITDA between $107 million and $123 million.
Analyze how earnings announcements historically affect stock price performance